Cassava Sciences | PTIE - Selling And Administration Expenses


Cassava Sciences reported $3.89M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Abbott USD 3.27B 138M Mar/2026
Amgen USD 1.58B 354M Mar/2026
Biogen USD 554.3M 128.2M Mar/2026
Cara Therapeutics USD 2.19M 2.45M Sep/2025
Cassava Sciences USD 3.89M 2.77M Mar/2026
Eisai JPY 119.54B 7.82B Mar/2026
Eli Lilly USD 2.93B 198M Mar/2026
Geron USD 35.42M 6.24M Mar/2026
J&J USD 6.03B 719M Mar/2026
Merck USD 2.67B 180M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Novavax USD 25.53M 1.34M Dec/2025
Pfizer USD 2.92B 1.16B Mar/2026
Roche Holding CHF 7.28B 3.99B Dec/2025